Patents by Inventor Jan Boren

Jan Boren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
    Patent number: 7038011
    Abstract: The present invention relates to the study and control of atherosclerosis through the modulation of LDL-proteoglycan binding at Site B (amino acids 3359–3369) of the apo-B100 protein in LDL. The invention encompasses methods of identifying compounds which modulate LDL-proteoglycan binding, methods of identifying compounds which modulate atherosclerotic lesion formation, and methods of modulating the formation of atherosclerotic lesions. The invention also encompasses mutant apo-B100 proteins and LDL which exhibit reduced proteoglycan binding while maintaining LDL-receptor binding, polynucleotides which encode these apo-B100 proteins, as well as cells and animals which express the mutant apo-B100 proteins.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: May 2, 2006
    Assignee: The Regents of the University of California
    Inventors: Thomas Innerarity, Jan Boren
  • Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
    Patent number: 6933284
    Abstract: The present invention relates to the study and control of atherosclerosis through the modulation of LDL-proteoglycan binding at Site B (amino acids 3359-3369) of the apo-B100 protein in LDL. The invention encompasses methods of identifying compounds which modulate LDL-proteoglycan binding, methods of identifying compounds which modulate atherosclerotic lesion formation, and methods of modulating the formation of atherosclerotic lesions. The invention also encompasses mutant apo-B100 proteins and LDL which exhibit reduced proteoglycan binding while maintaining LDL-receptor binding, polynucleotides which encode these apo-B100 proteins, as well as cells and animals which express the mutant apo-B100 proteins.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: August 23, 2005
    Assignee: The Regents of the University of California
    Inventors: Thomas Innerarity, Jan Boren
  • Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
    Patent number: 6579682
    Abstract: The present invention relates to the study and control of atherosclerosis through the modulation of LDL-proteoglycan binding at Site B (amino acids 3359-3369) of the apo-B100 protein in LDL. The invention encompasses methods of identifying compounds which modulate LDL-proteoglycan binding, methods of identifying compounds which modulate atherosclerotic lesion formation, and methods of modulating the formation of atherosclerotic lesions. The invention also encompasses mutant apo-B100 proteins and LDL which exhibit reduced proteoglycan binding while maintaining LDL-receptor binding, polynucleotides which encode these apo-B100 proteins, as well as cells and animals which express the mutant apo-B100 proteins.
    Type: Grant
    Filed: March 5, 1999
    Date of Patent: June 17, 2003
    Assignee: The Regents of University of California
    Inventors: Thomas Innerarity, Jan Boren
  • Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
    Publication number: 20010029027
    Abstract: The present invention relates to the study and control of atherosclerosis through the modulation of LDL-proteoglycan binding at Site B (amino acids 3359-3369) of the apo-B100 protein in LDL. The invention encompasses methods of identifying compounds which modulate LDL-proteoglycan binding, methods of identifying compounds which modulate atherosclerotic lesion formation, and methods of modulating the formation of atherosclerotic lesions. The invention also encompasses mutant apo-B100 proteins and LDL which exhibit reduced proteoglycan binding while maintaining LDL-receptor binding, polynucleotides which encode these apo-B100 proteins, as well as cells and animals which express the mutant apo-B100 proteins.
    Type: Application
    Filed: March 29, 2001
    Publication date: October 11, 2001
    Inventors: Thomas Innerarity, Jan Boren
  • Methods and tools for identifying compounds which modulate atherosclerosis by impacting LDL-proteoglycan binding
    Publication number: 20010024797
    Abstract: The present invention relates to the study and control of atherosclerosis through the modulation of LDL-proteoglycan binding at Site B (amino acids 3359-3369) of the apo-B100 protein in LDL. The invention encompasses methods of identifying compounds which modulate LDL-proteoglycan binding, methods of identifying compounds which modulate atherosclerotic lesion formation, and methods of modulating the formation of atherosclerotic lesions. The invention also encompasses mutant apo-B100 proteins and LDL which exhibit reduced proteoglycan binding while maintaining LDL-receptor binding, polynucleotides which encode these apo-B100 proteins, as well as cells and animals which express the mutant apo-B100 proteins.
    Type: Application
    Filed: March 29, 2001
    Publication date: September 27, 2001
    Inventors: Thomas Innerarity, Jan Boren